Retrospective Comparison of 5 different Methods for Long-Term LDL-Apheresis in 20 Patients between 1986 and 2001
- 1 February 2004
- journal article
- research article
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 27 (2) , 137-148
- https://doi.org/10.1177/039139880402700209
Abstract
Purpose: To compare long-term efficacy and biocompatibility of the 5 most commonly applied LDL-apheresis techniques using a specifically modified calculation method of the area under the curve (AUC) for laboratory parameters. Design: Retrospective long-term analysis of 20 patients with homozygous or severe heterozygous familial hypercholesterolemia. Procedures: The following 5 extra-corporeal LDL-apheresis methods were compared: IMAL (Immuno Adsorption of Lipoproteins), DSA (Dextran Sulphate Adsorption), HELP (Heparin Induced Extra-corporeal LDL Precipitation), DALI (Direct Adsorption of Lipoproteins), MDF (Membrane Differential Filtration). Main outcome measures: AUC derived plasma concentrations (CAUC) of lipoproteins between two apheresis procedures and their long-term course. Comparison of biocompatibility and efficacy concerning the LDL-C target of < 2.6 mmol/L of 5 apheresis techniques. Progression of atherosclerosis in patients with severe hypercholesterolemia. Main findings: The means of AUC derived average plasma concentrations (CAUC) of all treatment intervals were for LDL-C and the LDL/HDL ratio as follows: IMAL (5.59 mmol/L; ratio 4.1), DSA (3.03 mmol/L; ratio 2.0), HELP (4.06 mmol/L; ratio 2.2), DALI (3.83 mmol/L; ratio 3.3), MDF (3.26 mmol/L; ratio 3.2). Coronary heart disease and cardiac events (myocardial infarction, PTCA/ stent implantation, CABG) progressed in only 2 patients whereas atherosclerosis manifestations (sclerosis abdominal aorta, carotid artery stenosis, peripheral vascular disease) worsened in 13 patients. Mean ergometric capacity improved from 112 to 118 Watt. Conclusions: All 5 apheresis methods (IMAL, DSA, HELP, DALI, MDF) proved to be safe and suitable for long-term treatment in patients with severe hypercholesterolemia. The introduction of the CAUC revealed that the target of LDL-C < 2.6 mmol/L was not achieved with regard to the time averaged concentration (CAUC).Keywords
This publication has 31 references indexed in Scilit:
- Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial HypercholesterolemiaCirculation, 2002
- Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemiaAtherosclerosis, 2000
- Analysis of the Long-Term Efficacy and Selectivity of Immunoadsorption Columns for Low Density Lipoprotein ApheresisAsaio Journal, 2000
- Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemiaThe American Journal of Cardiology, 1998
- Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 menAtherosclerosis, 1997
- No evidence for feedback inhibition of hepatic apolipoprotein B (apo B) production after extracorporeal low density lipoprotein precipitation as determined by [I‐13C]leucine infusion in normal volunteersEuropean Journal of Clinical Investigation, 1993
- LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitorsThe Lancet, 1993
- The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease.European Journal of Clinical Investigation, 1991
- Plasma fibrinogen and coronary risk factors: The Scottish heart health studyJournal of Clinical Epidemiology, 1990
- Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemiaAtherosclerosis, 1978